-- title: "Feline Upper Respiratory Tract Infection Complex: Multiplex PCR Panel Interpretation and Treatment Algorithms" category: "molecular" metaDescription: "A technical reference for interpreting multiplex PCR results in feline upper respiratory infection, including cycle threshold cutoffs and evidence-based treatment algorithms for herpesvirus, calicivirus, Bordetella bronchiseptica, and Mycoplasma felis." primaryKeyword: "feline respiratory multiplex PCR" secondaryKeywords: ["feline herpesvirus-1 cycle threshold", "feline calicivirus Ct values", "Bordetella bronchiseptica treatment", "Mycoplasma felis antimicrobial stewardship", "upper respiratory infection algorithm cats"]

Feline Upper Respiratory Tract Infection Complex: Multiplex PCR Panel Interpretation and Treatment Algorithms

Introduction

Feline upper respiratory tract infection (URI) complex represents a syndromic grouping of viral and bacterial pathogens that cause clinically overlapping signs, including serous to mucopurulent ocular and nasal discharge, sneezing, conjunctivitis, oral ulceration, and in severe cases, pneumonia. The primary etiological agents are feline herpesvirus-1 (FHV-1; a DNA virus in the family Herpesviridae, subfamily Alphaherpesvirinae), feline calicivirus (FCV; a positive-sense single-stranded RNA virus in the family Caliciviridae), and the bacteria Bordetella bronchiseptica (a Gram-negative coccobacillus) and Mycoplasma felis (a cell wall-deficient mollicute) [8, 10]. Co-infections occur frequently, and clinical signs alone are insufficient for pathogen-specific diagnosis [10]. Multiplex real-time PCR (qPCR/RT-qPCR) panels have become the standard for simultaneous detection and differentiation of these agents, providing cycle threshold (Ct) values that correlate with nucleic acid load. This article provides a technical framework for interpreting multiplex PCR results, deriving actionable treatment algorithms, and integrating antimicrobial stewardship principles.

Etiological Agents and Their Clinical Profiles

Feline Herpesvirus-1 (FHV-1)

FHV-1 is an enveloped, double-stranded DNA virus that establishes lifelong latency in trigeminal ganglia. Primary infection typically causes acute keratoconjunctivitis, sneezing, and nasal discharge. Reactivation under stress leads to recrudescent disease. In naive kittens, morbidity is high and mortality can occur secondary to viral pneumonia secondary to secondary bacterial infection. The virus is cytolytic for respiratory epithelium, causing syncytia and intranuclear eosinophilic inclusion bodies. Mucosal immunity is short-lived, and vaccination reduces severity but does not prevent infection or latency.

Feline Calicivirus (FCV)

FCV is a non-enveloped, positive-sense RNA virus notable for its high mutation rate and antigenic diversity. Classic strains cause oral ulceration (especially on the tongue and hard palate), salivation, and mild conjunctivitis. Emerging virulent systemic FCV strains induce a systemic febrile illness with edema, icterus, and multi-organ necrosis; these are associated with specific capsid mutations [11]. FCV is also a key differential for feline lower respiratory disease, as it can cause interstitial pneumonia. The virus is resistant to many disinfectants due to its non-enveloped structure.

Bordetella bronchiseptica

This Gram-negative bacterium colonizes ciliated respiratory epithelium and produces toxins that impair mucociliary clearance. In cats, it is associated with mild to moderate cough, nasal discharge, and occasional bronchopneumonia. Kittens and immunosuppressed adults are at highest risk. Transmission is direct or via fomites. The organism is intrinsically resistant to some beta-lactams but susceptible to tetracyclines and fluoroquinolones.

Mycoplasma felis

M. felis is a commensal of the feline respiratory tract but can act as an opportunistic pathogen, especially in kittens and cats with concurrent viral infections. It causes conjunctivitis, sneezing, and occasional lower respiratory involvement. Diagnosis requires PCR because the organism does not grow on standard media. M. felis lacks a cell wall, making beta-lactams ineffective; tetracyclines and macrolides are first-line treatments.

Multiplex PCR Assay Design and Principle

Commercial and laboratory-developed multiplex qPCR/RT-qPCR panels for feline respiratory pathogens typically co-amplify FHV-1 (DNA polymerase gene), FCV (viral capsid or RNA-dependent RNA polymerase gene), Bordetella bronchiseptica (e.g., the flaA gene or its pertussis toxin ortholog), and M. felis (16S rRNA gene). Internal control (e.g., feline endogenous retrovirus or beta-actin) monitors sample adequacy and extraction efficiency. Detection uses hydrolysis probes with distinct fluorophores (e.g., FAM, VIC, Cy5, Texas Red). The RT step is required for RNA viruses (FCV). A validated multiplex assay capable of simultaneous detection of these four agents plus a control has been described [12]; such assays demonstrate high analytical sensitivity, often 10-100 copies per reaction.

Cycle threshold (Ct) values are inversely proportional to the log of the target copy number. A Ct value of 35 is often the limit of detection; samples with Ct above 35 may be reported as negative or equivocal depending on laboratory cutoffs. Quantitation can be reported as genome equivalents per milliliter of swab eluate if standard curves are included.

Critical Pre-Analytical Variables

• Swab type: Flocked nylon swabs with synthetic fibers (not cotton) maximize cell collection and nucleic acid release.
• Transport medium: Inactivation medium (e.g., guanidine-based) preserves RNA and DNA and ensures biosafety.
• Storage: Samples should be processed within 48 hours or stored at -80°C for longer intervals; freeze-thaw cycles degrade RNA.

Ct Value Interpretation and Clinical Correlation

Interpretation of Ct values must be considered in the context of clinical signs and vaccination history. The following table provides general interpretive thresholds based on published studies and clinical consensus [8, 10, 12, 11].

Vaccination with modified-live FHV-1 vaccines produces detectable viral replication in the upper respiratory tract for up to 14 days post-administration, resulting in Ct values in the 30-35 range. A history of recent vaccination should be documented to avoid misdiagnosis [10]. In contrast, FCV vaccines are inactivated or recombinant and do not produce shedding that interferes with PCR detection.

Treatment Algorithms Based on Multiplex PCR Results

The treatment approach must be guided by the primary pathogen identified, severity of clinical signs, and antimicrobial stewardship principles. Empiric antibiotics should be avoided in confirmed viral monoinfections unless secondary bacterial infection is suspected (e.g., by a shift from serous to mucopurulent discharge or by cytology showing intracellular bacteria). The algorithm below integrates these considerations.

Mermaid Decision Flow Diagram

flowchart TD
    A[Clinical signs of feline URI], > B[Collect conjunctival / oropharyngeal swab]
    B, > C[Multiplex RT-qPCR / qPCR panel]
    C, > D{Pathogen(s) detected?}
    
    D, FHV-1 only, > E[FHV-1 positive]
    E, > E1[Supportive care: antivirals?]
    E1, > E2{Severe signs / kitten?}
    E2, Yes, > E3[Consider famciclovir 90 mg/kg PO TID]
    E2, No, > E4[Supportive care only: L-lysine? Controversial]
    E3, > E5[Monitor; recheck if no improvement in 7 days]
    E4, > E5
    
    D, FCV only, > F[FCV positive]
    F, > F1{Severe systemic signs?}
    F1, Yes, > F2[Isolate; supportive care +/- interferon]
    F1, No, > F3[Supportive care; oral hygiene; NSAIDs (meloxicam) for oral ulcers?]
    F2, > F4[Monitor for virulent systemic FCV]
    F3, > F4
    
    D, B. bronchiseptica only, > G[Bordetella positive]
    G, > G1{Treatment indicated?}
    G1, Ct <30 or signs present, > G2[Doxycycline 5 mg/kg PO BID x 7-14 days]
    G1, Ct >30 and no signs, > G3[Consider no treatment; monitor]
    G2, > G4[Recheck if signs persist >5 days; consider culture]
    
    D, M. felis only, > H[Mycoplasma positive]
    H, > H1{Conjunctivitis?}
    H1, Yes, > H2[Doxycycline 5 mg/kg PO BID x 14-21 days]
    H1, No respiratory signs, > H3[No treatment; monitor]
    
    D, Co-infection (viral + bacterial), > I[Combination treatment]
    I, > I1[Treat viral component per above]
    I1, > I2[Treat bacterial component per above]
    I2, > I3[Avoid fluoroquinolones unless culture-guided; doxycycline often covers both Bordetella and Mycoplasma]
    
    D, All negative, > J[Consider other causes]
    J, > J1[Fungal (Cryptococcus? Aspergillus?); foreign body; neoplasia]
    J1, > J2[Advanced imaging; biopsy; serology for Cryptococcus]

Antimicrobial Stewardship Guidance

The overuse of broad-spectrum antibiotics in feline URI must be curbed. Multiplex PCR provides objective evidence to guide targeted therapy.

• For confirmed viral monoinfection, antibiotics are not indicated unless secondary bacterial infection is confirmed by cytology or culture. In kittens with severe mucopurulent discharge, doxycycline is a reasonable first line given its activity against B. bronchiseptica, M. felis, and Chlamydia felis (the latter not covered by the four-plex panel but prevalent in some populations) [8, 10].
• Doxycycline is preferred for both Bordetella and Mycoplasma; it is safe in cats if properly administered (tablet or compounded liquid; avoid doxycycline hyclate due to esophageal stricture risk).
• Fluoroquinolones (e.g., marbofloxacin, pradofloxacin) should be reserved for cases with documented resistance or lack of response to doxycycline. Pradofloxacin has good activity against Mycoplasma but may increase the risk of Gram-negative resistance.
• Azithromycin is an alternative for Bordetella and Mycoplasma but carries higher gastrointestinal side effects in cats.
• Corticosteroids should be avoided in acute infection with detectable high-load virus, as they may exacerbate viral replication. NSAIDs (meloxicam, robenacoxib) can be used for oral ulcer pain and inflammation in FCV cases, provided the cat is well-hydrated and renal function is normal.

The duration of therapy should be guided by clinical response. For Mycoplasma, 14-21 days is typical; for Bordetella, 7-14 days. Re-testing by PCR after treatment is not routinely recommended unless clinical signs persist; a negative PCR can confirm clearance but may be confounded by residual nucleic acid.

Differential Considerations and Advanced Diagnostics

If multiplex PCR results are negative despite strong clinical suspicion, consider these additional diagnostic pathways:

• Fungal culture or PCR for Cryptococcus neoformans/gattii: especially in endemic areas or with nasal granuloma [1]. Feline cryptococcosis can mimic URI with sneezing and nasal discharge.
• Mycobacterium orygis and other Mycobacterium species: rare but emerging zoonotic pathogens that can cause lower respiratory disease and lymphadenitis in cats. PCR and culture for mycobacteria require specific conditions [2].
• Influenza A virus (including H5N1): documented infections in cats, often with severe pneumonia; requires specialized assays (e.g., CDC flu panel) and public health reporting [5, 7].
• SARS-CoV-2: cats are susceptible and can develop mild respiratory signs; reverse zoonosis potential [4, 6, 9, 14]. While not part of the standard feline URI panel, multiplex assays including SARS-CoV-2 have been developed [12].
• Foreign body, nasopharyngeal polyp, or neoplasia: require advanced imaging (CT, rhinoscopy) for definitive diagnosis.

Computational Modeling and Bioinformatics Support

Quantitative PCR results (Ct values) from multiplex panels can be integrated into computational models to predict outbreak risk and pathogen co-occurrence patterns. For example, seasonal and geographic clustering of FHV-1 and FCV has been modeled using Bayesian spatiotemporal frameworks derived from diagnostic laboratory data [8, 10]. Machine learning classifiers (random forest, gradient boosting) trained on Ct values and clinical metadata can improve diagnostic accuracy and predict treatment response. The use of foundation models for host tropism prediction, as described for emerging viruses Biological Foundation Models for Veterinary Virology: Predicting Host Tropism and Pathogenicity, may also be adapted to predict feline susceptibility to novel respiratory pathogens based on receptor binding dynamics [6, 14].

Conclusion

Multiplex PCR panels for feline respiratory pathogens provide a precise, quantitative tool to differentiate FHV-1, FCV, Bordetella bronchiseptica, and Mycoplasma felis. Interpretation of Ct values, coupled with vaccination history and clinical severity, enables targeted antiviral or antimicrobial therapy and reduces unnecessary antibiotic use. Treatment algorithms that stratify by pathogen and Ct threshold support antimicrobial stewardship while optimizing clinical outcomes. Clinicians should remain alert to pathogens not covered by standard panels, including fungal, mycobacterial, and novel viral agents, especially in cases with negative PCR results and persistent signs. Adoption of standardized multiplex assays and computational decision aids will enhance the evidence-based management of feline URI complex.

References

1. Dzimira S. Feline Cryptococcosis: Two Case Reports and a Literature Review. Pathogens. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41901732/
2. Mitra N, Jadhao A, Dhende AV, et al. First report of fatal feline pulmonary tuberculosis caused by the emerging zoonotic pathogen Mycobacterium orygis in a cat from India. Vet Res Commun. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41712109/
3. Luo D, Xie W, Li N, et al. Identification and Pathogenicity Analysis of Feline Calicivirus in Shanghai and Guangdong, China. Transbound Emerg Dis. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40503218/
4. Gunasekara S, Shatnawi S, More S, et al. Comparative analysis of neutrophil dynamics and disease in SARS-CoV-2 Delta and Omicron variants utilizing an in vivo feline model for COVID-19. Front Immunol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40475786/
5. Mena A, von Fricken ME, Anderson BD. The Impact of Highly Pathogenic Avian Influenza H5N1 in the United States: A Scoping Review of Past Detections and Present Outbreaks. Viruses. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40143238/
6. Qiao P, Yue C, Peng W, et al. Precise motif and cross-presentation of coronavirus peptides by feline MHC class I: implications for the mild infection of SARS-CoV-2. J Immunol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40073263/
7. Brüssow H. The Arrival of Highly Pathogenic Avian Influenza Viruses in North America, Ensuing Epizootics in Poultry and Dairy Farms and Difficulties in Scientific Naming. Microb Biotechnol. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39641589/
8. Umar S, Muhammad S, Mouzahim M, et al. Burden of Common Respiratory Pathogens Among Cats in China. Vet Med Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/39575527/
9. Gunasekara S, Tamil Selvan M, Murphy CL, et al. Characterization of Neutrophil Functional Responses to SARS-CoV-2 Infection in a Translational Feline Model for COVID-19. Int J Mol Sci. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39337543/
10. Ju H, Yang D, Jin J, et al. Spectrum detection and analysis of the epidemiological characteristics of infectious pathogens in the feline respiratory tract. Arch Virol. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39147982/
11. Wei Y, Zeng Q, Gou H, et al. Update on feline calicivirus: viral evolution, pathogenesis, epidemiology, prevention and control. Front Microbiol. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38756726/
12. Thieulent CJ, Carossino M, Peak L, et al. Development and validation of multiplex one-step qPCR/RT-qPCR assays for simultaneous detection of SARS-CoV-2 and pathogens associated with feline respiratory disease complex. PLoS One. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38517847/
13. Wang F, Yang G, Yan L. Crystal Structures of Fusion Cores from CCoV-HuPn-2018 and SADS-CoV. Viruses. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38400047/
14. Aloufi AS, El-Arabey AA, Eltayb WA, et al. Molecular dynamic analyses of the interaction of SARS-CoV-1 or 2 variants with various angiotensin-converting enzyme-2 species. J Biomol Struct Dyn. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/38344933/
15. Giner J, Lebrero ME, Trotta M, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in household domestic ferrets (Mustela putorius furo) in Spain, 2019-2023. Vet Res Commun. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/37548874/